{"brief_title": "A Comparison of Lamivudine and Zidovudine, Used Alone and Together, in HIV-Infected Patients Who Have Not Used Zidovudine in the Past", "brief_summary": "To evaluate the safety and efficacy of high-dose lamivudine (3TC) alone versus zidovudine (AZT) alone versus 3TC at high and low doses in combination with AZT in HIV-1 infected patients. PER 02/27/95 AMENDMENT: To evaluate the efficacy and safety of both blinded and open-label combination therapy.", "detailed_description": "Patients are randomized to one of four treatment arms: 3TC alone, AZT alone, low-dose 3TC plus AZT, or high-dose 3TC plus AZT. Patients receive treatment for 32 weeks, with possible extension to 52 weeks. PER 02/27/95 AMENDMENT: Patients may continue therapy on AZT and low-dose 3TC on an open-label basis. Open-label therapy continues with follow-up every 8 weeks until intolerable toxicity occurs or study terminates.", "condition": "HIV Infections", "intervention_type": "Drug", "intervention_name": "Zidovudine", "criteria": "Inclusion Criteria Patients must have: - HIV positivity. - CD4 count 200-500 cells/mm3. - AZT naive status (<= 4 weeks of prior AZT). Exclusion Criteria Patients with the following prior condition are excluded: History of intolerance to AZT. Prior Medication: Excluded: - More than 4 weeks of prior AZT. - Any prior antiretroviral treatment other than AZT.", "gender": "All", "minimum_age": "12 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00002320.xml"}